Autopsy report · NCT00403052

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

“Administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Dynavax Technologies Corporation

Sponsor type

Industry

Conditions

Colorectal Neoplasms

Interventions

1018 ISS immunostimulatory oligonucleotide

Participants

14

Sites

3

Countries

United States

Trials that died the same way

• An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
  “Administrative Reason” (94% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (77% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (73% match in meaning)
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
  “Business reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.